Related Content
Press Release
Press Release
This is archived content from the U.S. Department of Justice website. The information here may be outdated and links may no longer function. Please contact webmaster@usdoj.gov if you have any questions about the archive site.
Note: View DEA Administrator Anne Milgram's remarks (YouTube).
Charges against five pharmaceutical distributor executives and five pharmaceutical sales representatives and brokers have been unsealed in the Southern District of Texas, Southern District of Florida, Eastern District of Missouri, and Eastern District of North Carolina as part of a larger enforcement action related to the unlawful distribution of nearly 70 million opioid pills and over 30 million doses of other commonly abused prescription drugs to alleged Houston-area pill-mill pharmacies. Three Houston-area pharmacy operators were also charged in the Southern District of Texas for their role in the schemes. Nine individuals have pleaded guilty.
According to court documents, the opioids allegedly distributed — oxycodone, hydrocodone, and hydromorphone — were available in numerous strengths and forms, but the distributors allegedly sold the drugs almost exclusively in their most abused, most powerful immediate-release pill forms — i.e., the ones that sold for the most money on the black market. The distributors also allegedly sold prescription drug potentiators — alprazolam, carisoprodol, and promethazine with codeine syrup — known for their reputation of enhancing the high from the opioids. The distributors allegedly charged their Houston customers far more for the drugs than what a legitimate pharmacy could or would pay.
“The defendants, including pharmaceutical drug distributors, allegedly exploited the opioid crisis for profit — selling dangerous and addictive drugs to pill-mill pharmacies at above-market prices, knowing that the drugs would end up on the black market,” said Principal Deputy Assistant Attorney General Nicole M. Argentieri, head of the Justice Department’s Criminal Division. “The drugs had a staggering black-market value of over $1.3 billion. These charges represent the Justice Department’s largest criminal enforcement action targeting executives, brokers, and alleged pill-mill pharmacy owners for unlawfully distributing opioids and other commonly abused drugs. Our message is clear: we will not hesitate in our pursuit of those involved in dumping addictive pharmaceutical drugs onto the streets.”
As alleged in the charging documents, the defendants mostly targeted pill-mill pharmacies in and around Houston — a nationally recognized “hot zone” for diversion of pharmaceutical opioids onto the black market. The distributors sought to thwart the Drug Enforcement Administration (DEA)'s oversight function in several ways, including by following what one defendant called a “blueprint” for avoiding detection: high prices, low purchasing limits for the controlled drugs, and compliance measures that only served appearances. In addition, the distributors were all located outside Texas, far removed from their Houston-area pill-mill pharmacy customers and the communities ravaged by their alleged offenses.
“The defendants in the charges announced today are alleged to be responsible for significantly contributing to the devastation caused by the opioid crisis by knowingly supplying pill-mill pharmacies and coaching pharmacy operators on how to evade law enforcement detection. According to the charging documents, they knowingly sold bulk narcotics to drug traffickers and to pharmacies they knew were selling to drug traffickers,” said DEA Administrator Anne Milgram. “As alleged, these defendants — owners, CEOs, executives, brokers — put profits over the health and safety of the American public. No one is above the law. If you contribute to the opioid epidemic, if you profit from the devastation of communities, we will hold you accountable. I commend the collaboration between DEA’s Diversion Control Division, our field divisions in St. Louis, Miami, Atlanta, Phoenix, Louisville and Houston, and our other state and federal law enforcement partners whose dedication to this investigation led us here today.”
“The distributors that sourced pills into the Houston area may be located across the country in Arizona, Florida, Maryland, California, North Carolina, and elsewhere, but they targeted Houston, helping to make it a known ‘hot zone’ for drug diversion,” said U.S. Attorney Alamdar S. Hamdani for the Southern District of Texas. “This office will always support the prosecution of individuals who try to thwart law enforcement and oversight by operating across state lines, posing as legitimate businesses, while in reality poisoning our district by targeting pill mills with precisely the drugs at the heart of our country’s addiction crisis. While there remain others who will be held accountable in the future, these cases build on this district’s history of systematically dismantling pill-mill clinics, pharmacies, and the often-violent drug-trafficking organizations, responsible for selling these pills in our community.”
“The use of protocols outside of common industry practice has contributed to the current opioid epidemic. To boost their profits, bad actors facilitate the distribution of opioids without medical necessity, threatening the lives and health of the public and the integrity of the Medicare program,” said Deputy Inspector General for Investigations Christian J. Schrank of the Department of Health and Human Services Office of Inspector General (HHS-OIG). “Our agency, working with our law enforcement partners, will continue to thoroughly investigate such schemes.”
“The FBI is dedicated to stopping dangerous controlled drugs from ending up in the wrong hands in communities across the country,” said Assistant Director Chad Yarbrough of the FBI Criminal Investigative Division. “These charges are another example of our continued multi-prong attack on those who contribute to the opioid crisis. The FBI and our partners investigate crimes at every level from the wholesaler pharmaceutical companies supplying the local pill-mill pharmacies to those selling the dangerous drugs on the street and black-market. We will not let anyone cash in and take advantage of people dealing with a drug addiction.”
“Supplying diverted prescription drugs undermines FDA safeguards designed to protect the public, compromising public safety for personal gain,” said Assistant Commissioner Justin Green of the Food and Drug Administration's Office of Criminal Investigations (FDA-OCI). “This investigation is a clear demonstration that the FDA will not stop pursuing and bringing to justice those who put the public health at risk.”
“Today’s charges are a reminder of the continued danger of the opioid epidemic and the resolve of the investigative and legal teams,” said Special Agent in Charge Jonathan Ulrich of the U.S. Postal Service's Office of Inspector General (USPS-OIG). “Anyone, including corporate executives, who knowingly facilitates opioid abuse will be held accountable for their greed and total disregard for safety.”
According to court documents, the following individuals were charged as part of today’s enforcement action:
A federal district court judge will determine any sentence after considering the U.S. Sentencing Guidelines and other statutory factors.
DEA, HHS-OIG, FBI, USPS-OIG, FDA-OCI, and MFCU investigated the case, with assistance from the Department of Homeland Security, General Services Administration Office of Inspector General, Broward Sheriff’s Office, Houston Police Department, and other federal and state law enforcement agencies.
Today’s enforcement action was led and coordinated by Trial Attorneys Drew Pennebaker and Devon Helfmeyer and Assistant Chief Aleza Remis of the Criminal Division’s Fraud Section's Health Care Fraud Unit. Trial Attorneys Drew Pennebaker and Devon Helfmeyer are prosecuting the cases, and Assistant U.S. Attorney Brandon Fyffe for the Southern District of Texas is assisting with forfeiture. The U.S. Attorneys’ Offices for the Southern District of Texas, Southern District of Florida, Eastern District of Missouri, and Eastern District of North Carolina assisted with the prosecutions.
The Fraud Section leads the Criminal Division’s efforts to combat health care fraud through the Health Care Fraud Strike Force Program. Since March 2007, this program, currently comprised of nine strike forces operating in 27 federal districts, has charged more than 5,400 defendants who collectively have billed federal health care programs and private insurers more than $27 billion. In addition, the Centers for Medicare & Medicaid Services, working in conjunction with HHS-OIG, are taking steps to hold providers accountable for their involvement in health care fraud schemes. More information can be found at www.justice.gov/criminal-fraud/health-care-fraud-unit.
An indictment is merely an allegation. All defendants are presumed innocent until proven guilty beyond a reasonable doubt in a court of law.